Induced pluripotent stem cell (iPSC)-derived immortalized megakaryocyte cell lines (imMKCLs) from voluntary blood component donors with specific HLA haplotypes towards platelet products in transfusion therapy.
- Conditions
- Thrombocytopenia
- Registration Number
- JPRN-UMIN000015345
- Lead Sponsor
- ?Center for iPS Cell Research and Application (CiRA), Kyoto University?Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 3
?Voluntary, non-remunerated, healthy blood component donors
?Homozygotes of HLA-A, HLA-B, and HLA-C
?Blood type O
?Individuals capable of giving voluntary, informed consent in writing
?The following viral infection:
Hepatic Virus B
Hepatic Virus C
Human Immunodeficiency Virus
Human T-cell leukemia virus
Human parvovirus B19
Cytomegalovirus
?The following microbial infection:
Treponema pallidum
West e Virus
Chlamydiaceae
Genus Neisseria
Mycobacterium
Malaria parasites(Plasmodium spp.)
Babesia
Trypanosoma cruzi
Leishmania
Trypanosoma brucei
?Malignant neoplasm
?Transmissible spongiform encephalopathy (including suspected case), Dementia or cognitive impairment, Stroke, Seizure
?The following conditions:
Particular or genetic/hereditary disorders
Severe or uncontrolled metabolic or endocrinal disorders
Connective tissue diseases
Severe or uncontrolled hematologic diseases
Severe or uncontrolled hepatic disorders
?Enrolling related studies of generating iPSC banks
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In vitro safety and functional studies by platelets generated from human iPSC-derived immortalized megakaryocyte cell lines
- Secondary Outcome Measures
Name Time Method